SG11201901307VA - Heterodimeric immunoglobulin constructs and preparation methods thereof - Google Patents
Heterodimeric immunoglobulin constructs and preparation methods thereofInfo
- Publication number
- SG11201901307VA SG11201901307VA SG11201901307VA SG11201901307VA SG11201901307VA SG 11201901307V A SG11201901307V A SG 11201901307VA SG 11201901307V A SG11201901307V A SG 11201901307VA SG 11201901307V A SG11201901307V A SG 11201901307VA SG 11201901307V A SG11201901307V A SG 11201901307VA
- Authority
- SG
- Singapore
- Prior art keywords
- tianzhu
- beijing
- international
- airport
- west road
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 1110101011111 011101 0 0111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/059502 Al 05 April 2018 (05.04.2018) WIP0 I PCT (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C07K 16/00 (2006.01) A61P 37/02 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61K 39/395 (2006.01) A61P 35/00 (2006.01) C12N 15/13 (2006.01) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (21) International Application Number: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, PCT/CN2017/104044 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 28 September 2017 (28.09.2017) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (25) Filing Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (26) Publication Language: English (30) Priority Data: Published: 201610863814.7 29 September 2016 (29.09.2016) CN — with international search report (Art. 21(3)) — (71) Applicant: BEIJING HANMI PHARMACEUTICAL with sequence listing part of description (Rule 5.2(a)) CO., LTD. [CN/CN]; No.10 Tianzhu West Road, Tianzhu Airport Industrial Zone A, Shunyi District, Beijing 101312 (CN). (72) Inventors: LIU, Jiawang; c/o Beijing Hanmi Pharmaceu- _ tical Co., Ltd., No. 10 Tianzhu West Road, Tianzhu Air- port, Industrial Zone A, Shunyi District, Beijing 101312 = (CN). SONG, Nanmeng; c/o Beijing Hanmi Pharmaceuti- _ cal Co., Ltd., No. 10 Tianzhu West Road, Tianzhu Airport, = _ Industrial Zone A, Shunyi District, Beijing 101312 (CN). = YANG, Dongge; c/o Beijing Hanmi Pharmaceutical Co., = Ltd., No. 10 Tianzhu West Road, Tianzhu Airport, Industri- = al Zone A, Shunyi District, Beijing 101312 (CN). YANG, = _ Yaping; c/o Beijing Hanmi Pharmaceutical Co., Ltd., No. _ 10 Tianzhu West Road, Tianzhu Airport, Industrial Zone A, Shunyi District, Beijing 101312 (CN). KIM, Maengsup; c/ o Beijing Hanmi Pharmaceutical Co., Ltd., No. 10 Tianzhu — West Road, Tianzhu Airport, Industrial Zone A, Shunyi Dis- trict, Beijing 101312 (CN). = Agent: BEIJING INTELLEGAL INTELLECTUAL (74) PROPERTY AGENT LTD.; 1802, 1803, 1805 Tower B, = _ _ Grand Place, No 5 Huizhong Road, Chaoyang District, Bei- jing 100101 (CN). = (81) Designated States (unless otherwise indicated, for every — kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = _ 1-1 ei © kr) 0\ kr) C:::: ) (54) Title: HETERODIMERIC IMMUNOGLOBULIN CONSTRUCTS AND PREPARATION METHODS THEREOF --.... 00 ,1 (57) : Provided is a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., Ws- = pecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can \" simultaneously bind two target molecules and are more potent in the treatment of complex diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610863814 | 2016-09-29 | ||
| PCT/CN2017/104044 WO2018059502A1 (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901307VA true SG11201901307VA (en) | 2019-03-28 |
Family
ID=61762488
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901307VA SG11201901307VA (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| SG10201913263SA SG10201913263SA (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913263SA SG10201913263SA (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11498977B2 (en) |
| EP (1) | EP3504234A4 (en) |
| JP (1) | JP7424727B2 (en) |
| KR (1) | KR102242990B1 (en) |
| CN (1) | CN109790215B (en) |
| AU (1) | AU2017336867B2 (en) |
| BR (1) | BR112019006074A2 (en) |
| CA (1) | CA3035681A1 (en) |
| CL (1) | CL2019000836A1 (en) |
| CO (1) | CO2019003133A2 (en) |
| DO (1) | DOP2019000079A (en) |
| EA (1) | EA201990285A1 (en) |
| EC (1) | ECSP19022190A (en) |
| IL (1) | IL265605B2 (en) |
| MX (1) | MX2019003563A (en) |
| MY (1) | MY194994A (en) |
| PE (1) | PE20190576A1 (en) |
| PH (1) | PH12019500655A1 (en) |
| SA (1) | SA519401441B1 (en) |
| SG (2) | SG11201901307VA (en) |
| TN (1) | TN2019000055A1 (en) |
| WO (1) | WO2018059502A1 (en) |
| ZA (1) | ZA201901708B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7031810B2 (en) | 2016-11-18 | 2022-03-08 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド | Anti-PD-1 / anti-HER2 natural antibody structural form heterodimeric bispecific antibody and method for producing the same. |
| JP7579703B2 (en) * | 2017-04-01 | 2024-11-08 | 北京韓美薬品有限公司 | Anti-PD-L1/anti-PD-1 natural antibody structure-mimicking heterodimer bispecific antibody and method for preparing same |
| SG11202005216XA (en) * | 2017-12-04 | 2020-07-29 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
| WO2019153200A1 (en) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof |
| CN111712522A (en) | 2018-02-11 | 2020-09-25 | 北京韩美药品有限公司 | anti-PD-1/anti-VEGF natural antibody structure-like heterodimer form bispecific antibody and preparation thereof |
| EP3762027A4 (en) * | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| TWI825214B (en) * | 2018-11-05 | 2023-12-11 | 中國大陸商北京韓美藥品有限公司 | Anti-tnfα/anti-il-17a natural antibody structure-like heterodimeric bispecific antibody, and preparation method thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN113121697B (en) * | 2019-12-31 | 2023-06-09 | 周易 | CH3 domain modification induced heterodimer and preparation method and application thereof |
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
| EP4200337A4 (en) * | 2020-08-24 | 2024-10-02 | Janux Therapeutics, Inc. | ANTIBODIES AGAINST TROP2 AND CD3 AND USES THEREOF |
| EP4276115A4 (en) * | 2021-01-08 | 2024-12-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY WITH HETERODIMERIC FORM OF A TYPE SIMILAR TO A STRUCTURE OF A NATURAL ANTIBODY ANTI-PD-1/ANTI-CD47 AND RELATED PREPARATION |
| MX2023008172A (en) * | 2021-01-08 | 2023-07-18 | Beijing Hanmi Pharmaceutical Co Ltd | BISPECIFIC ANTIBODY OF A HETERODIMERIC FORM SIMILAR TO THE STRUCTURE OF THE NATURAL ANTI-PD-L1/ANTI-4-1BB ANTIBODY AND PREPARATION THEREOF. |
| US20250223379A1 (en) * | 2021-01-11 | 2025-07-10 | Adimab, Llc | Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof |
| KR20230147092A (en) * | 2021-01-22 | 2023-10-20 | 바이원큐어 테라퓨틱스, 인크. | Anti-HER-2/TROP-2 constructs and uses thereof |
| KR20230060546A (en) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | ANTIGEN BINDING PROTEINS WITH TWO Fc DOMAINS AND USE THEREOF |
| CN114539420B (en) * | 2022-01-20 | 2024-05-17 | 荣昌生物制药(烟台)股份有限公司 | Anti-B7-H3 monoclonal antibody, anti-B7-H3 xCD 3 bispecific antibody, preparation method and application thereof |
| AU2023210951A1 (en) * | 2022-01-26 | 2024-07-04 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-her2/trop2 antibodies and uses thereof |
| EP4482585A1 (en) | 2022-02-23 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| EP4482865A1 (en) * | 2022-02-24 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
| WO2025092987A1 (en) * | 2023-11-03 | 2025-05-08 | 拓济医药（苏州）有限责任公司 | Fc region-based heterodimer molecule and use thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9100352A (en) | 1991-02-27 | 1992-09-16 | Hoogovens Groep Bv | METHOD FOR MANUFACTURING IRON FOIL BY ELECTRODE POSITION. |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE4429450A1 (en) * | 1993-08-25 | 1995-03-02 | Osberger Helmut Jun | Yeast/fresh cell/enzyme beverage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ID27512A (en) | 1998-04-21 | 2001-04-12 | Microment Ges Fur Biomedizinis | PRIVATE POLIPEPTIDES CD19XCD3 AND ITS USES |
| CN1305896C (en) | 1998-05-06 | 2007-03-21 | 基因技术股份有限公司 | Protein purification by ion exchange chromatography |
| DK3483183T3 (en) | 2002-03-01 | 2021-06-21 | Immunomedics Inc | IMMUNO CONJUGATE INCLUDING HUMANIZED RS7 ANTIBODIES |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| CN102131828B (en) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | Antibody against human programmed death receptor PD-1 |
| PL2235064T3 (en) | 2008-01-07 | 2016-06-30 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| PT4209510T (en) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EA201171259A1 (en) * | 2009-04-22 | 2012-05-30 | Мерк Патент Гмбх | ANTIBODY HYBRID PROTEINS WITH MODIFIED FCRN BINDING SITES |
| AU2010321720B2 (en) * | 2009-11-23 | 2017-03-02 | Amgen Inc. | Monomeric antibody Fc |
| KR101973930B1 (en) * | 2010-11-05 | 2019-04-29 | 자임워크스 인코포레이티드 | Stable heterodimeric antibody design with mutations in the fc domain |
| EA201791693A1 (en) | 2011-03-25 | 2018-05-31 | Гленмарк Фармасьютикалс С.А. | HETERODIMERNY IMMUNOHLOBULINS |
| KR101970025B1 (en) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Antibodies and other molecules that bind b7-h1 and pd-1 |
| JP6475017B2 (en) | 2011-10-27 | 2019-02-27 | ゲンマブ エー／エス | Production of heterodimeric protein |
| KR102052774B1 (en) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Stable heterodimeric antibody design with mutations in the fc domain |
| WO2014067011A1 (en) * | 2012-11-02 | 2014-05-08 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| CN114163530B (en) | 2012-04-20 | 2025-04-29 | 美勒斯公司 | Methods and means for producing immunoglobulin-like molecules |
| EP3401337A1 (en) * | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| MX385344B (en) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | GENETICALLY MODIFIED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND THEIR USES. |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| RU2019118257A (en) | 2012-12-03 | 2019-06-24 | Новиммун С.А. | ANTI-CD47 ANTIBODIES AND METHODS OF THEIR APPLICATION |
| ES2827679T3 (en) | 2013-08-20 | 2021-05-24 | Merck Sharp & Dohme | Cancer treatment with a combination of a PD-1 antagonist and dinaciclib |
| AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody Molecules of PD-1 and Their Uses |
| ES2751915T5 (en) | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Immunoglobulin fusion proteins with SIRP alpha |
| WO2016057933A1 (en) | 2014-10-10 | 2016-04-14 | Global Biopharma, Inc. | Methods for treating and/or preventing a tumor growth, invasion and/or metastasis |
| SG10202007176TA (en) | 2014-12-30 | 2020-08-28 | Celgene Corp | Anti-cd47 antibodies and uses thereof |
| BR112017015136A2 (en) | 2015-01-14 | 2018-01-30 | Compass Therapeutics Llc | multispecific immunomodulator antigen binding construct polypeptide, multispecific immunomodulator antigen binding construct, conjugate, pharmaceutical composition, method for treating an individual with cancer, method for inhibiting or reducing cancer growth, composition, cell, method of making a polypeptide of multispecific immunomodulatory antigen binding construct, vector or vector set and kit |
| WO2016170039A1 (en) | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
| TWI870335B (en) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | Variant chimeric 4d5 antibodies and uses thereof in combination with anti-pd-1 antibodies for the treatment of cancer |
| CN105111314B (en) | 2015-08-13 | 2019-01-08 | 成都百世博生物技术有限公司 | Novel fusion protein, pharmaceutical composition, preparation method and application thereof |
| CN105175545B (en) | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | An anti-VEGF-anti-PD-1 bifunctional antibody and its application |
| CN106883297B (en) | 2015-12-16 | 2019-12-13 | 苏州康宁杰瑞生物科技有限公司 | CH3 domain-based heterodimer molecule, preparation method and application thereof |
| CA3010027A1 (en) | 2015-12-28 | 2017-07-06 | Massachusetts Institute Of Technology | Bispecific antibodies having constant region mutations and uses therefor |
| WO2017167350A1 (en) | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| GB201611530D0 (en) | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| WO2018068336A1 (en) | 2016-10-15 | 2018-04-19 | Innovent Biologics (Suzhou) Co., Ltd | Pd-1 antibodies |
| JP7031810B2 (en) * | 2016-11-18 | 2022-03-08 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド | Anti-PD-1 / anti-HER2 natural antibody structural form heterodimeric bispecific antibody and method for producing the same. |
| JP7579703B2 (en) * | 2017-04-01 | 2024-11-08 | 北京韓美薬品有限公司 | Anti-PD-L1/anti-PD-1 natural antibody structure-mimicking heterodimer bispecific antibody and method for preparing same |
| AR112603A1 (en) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS |
| CN107325184A (en) | 2017-08-08 | 2017-11-07 | 安徽大学 | Bispecific antibody targeting EGFR and HER2 and application thereof |
| EA039662B1 (en) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Antibodies specific to cd47 and pd-l1 |
| SG11202005216XA (en) * | 2017-12-04 | 2020-07-29 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
| WO2019153200A1 (en) * | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof |
| CN111712522A (en) * | 2018-02-11 | 2020-09-25 | 北京韩美药品有限公司 | anti-PD-1/anti-VEGF natural antibody structure-like heterodimer form bispecific antibody and preparation thereof |
| TWI825214B (en) * | 2018-11-05 | 2023-12-11 | 中國大陸商北京韓美藥品有限公司 | Anti-tnfα/anti-il-17a natural antibody structure-like heterodimeric bispecific antibody, and preparation method thereof |
-
2017
- 2017-09-28 CN CN201780060756.7A patent/CN109790215B/en active Active
- 2017-09-28 PE PE2019000733A patent/PE20190576A1/en unknown
- 2017-09-28 AU AU2017336867A patent/AU2017336867B2/en active Active
- 2017-09-28 IL IL265605A patent/IL265605B2/en unknown
- 2017-09-28 JP JP2019516702A patent/JP7424727B2/en active Active
- 2017-09-28 MX MX2019003563A patent/MX2019003563A/en unknown
- 2017-09-28 WO PCT/CN2017/104044 patent/WO2018059502A1/en not_active Ceased
- 2017-09-28 BR BR112019006074A patent/BR112019006074A2/en unknown
- 2017-09-28 MY MYPI2019001672A patent/MY194994A/en unknown
- 2017-09-28 SG SG11201901307VA patent/SG11201901307VA/en unknown
- 2017-09-28 TN TNP/2019/000055A patent/TN2019000055A1/en unknown
- 2017-09-28 EA EA201990285A patent/EA201990285A1/en unknown
- 2017-09-28 CA CA3035681A patent/CA3035681A1/en active Pending
- 2017-09-28 US US16/337,854 patent/US11498977B2/en active Active
- 2017-09-28 SG SG10201913263SA patent/SG10201913263SA/en unknown
- 2017-09-28 EP EP17854952.3A patent/EP3504234A4/en active Pending
- 2017-09-28 KR KR1020197009091A patent/KR102242990B1/en active Active
-
2019
- 2019-03-19 ZA ZA2019/01708A patent/ZA201901708B/en unknown
- 2019-03-26 PH PH12019500655A patent/PH12019500655A1/en unknown
- 2019-03-28 DO DO2019000079A patent/DOP2019000079A/en unknown
- 2019-03-28 CL CL2019000836A patent/CL2019000836A1/en unknown
- 2019-03-28 SA SA519401441A patent/SA519401441B1/en unknown
- 2019-03-29 CO CONC2019/0003133A patent/CO2019003133A2/en unknown
- 2019-03-29 EC ECSENADI201922190A patent/ECSP19022190A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201990285A1 (en) | 2019-12-30 |
| PE20190576A1 (en) | 2019-04-22 |
| SG10201913263SA (en) | 2020-03-30 |
| TN2019000055A1 (en) | 2020-07-15 |
| KR20190055813A (en) | 2019-05-23 |
| SA519401441B1 (en) | 2022-12-27 |
| NZ750566A (en) | 2024-04-26 |
| PH12019500655A1 (en) | 2019-08-05 |
| JP7424727B2 (en) | 2024-01-30 |
| WO2018059502A1 (en) | 2018-04-05 |
| KR102242990B1 (en) | 2021-04-22 |
| MY194994A (en) | 2022-12-30 |
| US20190284299A1 (en) | 2019-09-19 |
| CO2019003133A2 (en) | 2019-04-12 |
| US11498977B2 (en) | 2022-11-15 |
| CN109790215B (en) | 2023-06-30 |
| BR112019006074A2 (en) | 2019-06-18 |
| EP3504234A1 (en) | 2019-07-03 |
| AU2017336867A1 (en) | 2019-02-28 |
| EP3504234A4 (en) | 2020-12-02 |
| ECSP19022190A (en) | 2019-05-31 |
| AU2017336867B2 (en) | 2024-03-14 |
| DOP2019000079A (en) | 2019-11-15 |
| IL265605A (en) | 2019-05-30 |
| ZA201901708B (en) | 2022-11-30 |
| CL2019000836A1 (en) | 2019-08-02 |
| IL265605B2 (en) | 2024-06-01 |
| IL265605B1 (en) | 2024-02-01 |
| CA3035681A1 (en) | 2018-04-05 |
| CN109790215A (en) | 2019-05-21 |
| JP2019535650A (en) | 2019-12-12 |
| MX2019003563A (en) | 2019-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201903222PA (en) | Alkylate gasoline composition with renewable naphtha and iso-octane | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807794VA (en) | Naphthene-containing distillate stream compositions and uses thereof | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |